Divalproex Sodium
Product Images NDC 50090-2795

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50090-2795). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
FDA Label Image

Figure 3 (Divalproex Fig3)

Figure 3 (Divalproex Fig3)
This appears to be a graph showing the % Reduction in CPS (Central Processing Unit) rate in high dose and low dose, with the number of patients on the y-axis and the level of improvement on the x-axis.*
FDA Label Image

Figure 4 (Divalproex Fig4)

Figure 4 (Divalproex Fig4)
This is a figure displaying the mean 4-week migraine rates for two studies comparing the use of a placebo versus delayed-release tablets of divalproex sodium for migraine treatment. The mean dose of divalproex sodium delayed-release tablets for study 1 was 1,087 mg/day, while for study 2, the dose ranged from 500 to 1,000 mg/day.*
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)
FDA Label Image

Label Image (Lbl500902795)

Label Image (Lbl500902795)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.